XLV241129C105000
- 0.00
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.
Spotlight on AbbVie: Analyzing the Surge in Options Activity
10 Health Care Stocks With Whale Alerts In Today's Session
Barclays's 'Bang-for-the-buck' Tail Hedging ETFs: HYG, XLF, IYR
How Is The Market Feeling About Thermo Fisher Scientific?
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Barclays's Options Trading Ideas: Buy XLP, Rent XLF, Sell XLB
Behind the Scenes of Eli Lilly's Latest Options Trends
Sector Update: Health Care Stocks Advance Pre-Bell Friday
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of US Farm Prices Data
Wednesday Ends With Index Decline | Wall Street Today
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
'Bunker' and 'Booster' Stocks in the U.S. – Which Would Perform Better in a Downturn Vs. Upturn?
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
UnitedHealth Group Analyst Ratings
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data